DK3634463T3 - Forbedret protokol til behandling af lupus nephritis - Google Patents

Forbedret protokol til behandling af lupus nephritis Download PDF

Info

Publication number: DK3634463T3
Authority: DK; Denmark
Prior art keywords: treatment; lupus nephritis; improved protocol; protocol; improved
Prior art date: 2017-05-12

Application number

DK18798594.0T

Other languages

English (en)

Inventor

Neil Solomons

Robert B Huizinga

Original Assignee

Aurinia Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-12

Filing date

2018-05-11

Publication date

2023-11-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64095925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3634463(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-05-11 Application filed by Aurinia Pharmaceuticals Inc filed Critical Aurinia Pharmaceuticals Inc

2023-11-27 Application granted granted Critical

2023-11-27 Publication of DK3634463T3 publication Critical patent/DK3634463T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)

DK18798594.0T 2017-05-12 2018-05-11 Forbedret protokol til behandling af lupus nephritis DK3634463T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201762505734P	2017-05-12	2017-05-12
US201762541612P	2017-08-04	2017-08-04
US15/835,219 US10286036B2 (en)	2017-05-12	2017-12-07	Protocol for treatment of lupus nephritis
PCT/IB2018/000828 WO2018207026A2 (en)	2017-05-12	2018-05-11	Improved protocol for treatment of lupus nephritis

Publications (1)

Publication Number	Publication Date
DK3634463T3 true DK3634463T3 (da)	2023-11-27

Family

ID=64095925

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18798594.0T DK3634463T3 (da)	2017-05-12	2018-05-11	Forbedret protokol til behandling af lupus nephritis

Country Status (25)

Country	Link
US (1)	US10286036B2 (da)
EP (2)	EP4257138A3 (da)
JP (4)	JP7050904B2 (da)
KR (2)	KR20240142619A (da)
CN (1)	CN111163794A (da)
AU (2)	AU2018266850B2 (da)
BR (1)	BR112019023766A2 (da)
CA (1)	CA3063040A1 (da)
CL (1)	CL2019003249A1 (da)
DK (1)	DK3634463T3 (da)
ES (1)	ES2965454T3 (da)
FI (1)	FI3634463T3 (da)
HR (1)	HRP20231469T1 (da)
HU (1)	HUE064984T2 (da)
IL (2)	IL310731A (da)
LT (1)	LT3634463T (da)
MX (1)	MX2022014618A (da)
MY (1)	MY203070A (da)
PL (1)	PL3634463T3 (da)
PT (1)	PT3634463T (da)
RS (1)	RS64959B1 (da)
SI (1)	SI3634463T1 (da)
SM (1)	SMT202300407T1 (da)
WO (1)	WO2018207026A2 (da)
ZA (1)	ZA201907460B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20190224275A1 (en)	2017-05-12	2019-07-25	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
US10286036B2 (en)	2017-05-12	2019-05-14	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
MX2023008246A (es) *	2021-01-15	2023-09-29	Aurinia Pharmaceuticals Inc	Protocolo para minimizar la neurotoxicidad del inhibidor de calcineurin.
US11896719B2 (en)	2022-01-24	2024-02-13	Calliditas Therapeutics Ab	Pharmaceutical compositions
WO2025141456A1 (en) *	2023-12-27	2025-07-03	Indena S.P.A.	Process for the preparation of voclosporin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5712084A (en)	1995-09-08	1998-01-27	Research Corporation Technologies, Inc.	Donor kidney viability test for improved preservation
ATE332917T1 (de)	2001-10-19	2006-08-15	Isotechnika Inc	Synthese von cyclosporin-analogen
CA2727642C (en) *	2001-10-19	2014-02-04	Isotechnika Inc.	Synthesis of cyclosporin analogs
PT1435910E (pt)	2001-10-19	2009-09-07	Isotechnika Inc	Novos pré-concentrados de microemulsão de análogos da ciclosporina
CL2004000366A1 (es)	2003-02-26	2005-01-07	Pharmacia Corp Sa Organizada B	USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
EA013122B1 (ru)	2005-04-06	2010-02-26	Бристол-Маерс Сквибб Компани	Способы лечения иммунных нарушений, связанных с пересадкой трансплантата, растворимым мутантным ctla4
US8628930B2 (en) *	2009-04-27	2014-01-14	Niigata University	Use of megalin in urine as marker for detecting renal disorder
US9679115B2 (en)	2010-02-02	2017-06-13	Kathrine P. Frey	Methods and devices for reducing transfusions during or after surgery and for improving quality of life and function in chronic disease
EP2767276B1 (en) *	2011-10-12	2018-10-03	SBI Pharmaceuticals Co., Ltd.	Improving / prophylactic agent for chronic kidney disease
US10286036B2 (en)	2017-05-12	2019-05-14	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis

2017
- 2017-12-07 US US15/835,219 patent/US10286036B2/en active Active
2018
- 2018-05-11 MY MYPI2019006598A patent/MY203070A/en unknown
- 2018-05-11 PL PL18798594.0T patent/PL3634463T3/pl unknown
- 2018-05-11 KR KR1020247031633A patent/KR20240142619A/ko active Pending
- 2018-05-11 EP EP23181300.7A patent/EP4257138A3/en active Pending
- 2018-05-11 HR HRP20231469TT patent/HRP20231469T1/hr unknown
- 2018-05-11 EP EP18798594.0A patent/EP3634463B9/en active Active
- 2018-05-11 BR BR112019023766-6A patent/BR112019023766A2/pt unknown
- 2018-05-11 ES ES18798594T patent/ES2965454T3/es active Active
- 2018-05-11 FI FIEP18798594.0T patent/FI3634463T3/fi active
- 2018-05-11 LT LTEPPCT/IB2018/000828T patent/LT3634463T/lt unknown
- 2018-05-11 WO PCT/IB2018/000828 patent/WO2018207026A2/en not_active Ceased
- 2018-05-11 SM SM20230407T patent/SMT202300407T1/it unknown
- 2018-05-11 PT PT187985940T patent/PT3634463T/pt unknown
- 2018-05-11 KR KR1020197036702A patent/KR102710584B1/ko active Active
- 2018-05-11 IL IL310731A patent/IL310731A/en unknown
- 2018-05-11 SI SI201831026T patent/SI3634463T1/sl unknown
- 2018-05-11 DK DK18798594.0T patent/DK3634463T3/da active
- 2018-05-11 AU AU2018266850A patent/AU2018266850B2/en active Active
- 2018-05-11 CN CN201880044395.1A patent/CN111163794A/zh active Pending
- 2018-05-11 JP JP2020512938A patent/JP7050904B2/ja active Active
- 2018-05-11 IL IL270552A patent/IL270552B2/en unknown
- 2018-05-11 CA CA3063040A patent/CA3063040A1/en active Pending
- 2018-05-11 RS RS20231084A patent/RS64959B1/sr unknown
- 2018-05-11 HU HUE18798594A patent/HUE064984T2/hu unknown
2019
- 2019-11-08 MX MX2022014618A patent/MX2022014618A/es unknown
- 2019-11-11 ZA ZA201907460A patent/ZA201907460B/en unknown
- 2019-11-13 CL CL2019003249A patent/CL2019003249A1/es unknown
2022
- 2022-03-29 JP JP2022054055A patent/JP7295305B2/ja active Active
2023
- 2023-06-08 JP JP2023094742A patent/JP2023113884A/ja active Pending
2024
- 2024-05-06 AU AU2024202977A patent/AU2024202977A1/en active Pending
2025
- 2025-08-08 JP JP2025133227A patent/JP2025163248A/ja active Pending

Also Published As

Publication number	Publication date
PL3634463T3 (pl)	2024-03-04
JP2023113884A (ja)	2023-08-16
IL270552A (en)	2020-01-30
US20180325995A1 (en)	2018-11-15
JP7295305B2 (ja)	2023-06-20
KR20240142619A (ko)	2024-09-30
MX2022014618A (es)	2023-01-30
KR20200007884A (ko)	2020-01-22
HRP20231469T1 (hr)	2024-03-01
FI3634463T3 (fi)	2023-11-16
JP7050904B2 (ja)	2022-04-08
CN111163794A (zh)	2020-05-15
RS64959B1 (sr)	2024-01-31
JP2025163248A (ja)	2025-10-28
JP2022095754A (ja)	2022-06-28
JP2020519695A (ja)	2020-07-02
EP3634463A2 (en)	2020-04-15
BR112019023766A2 (pt)	2020-05-26
EP3634463B9 (en)	2024-01-10
RU2019140834A3 (da)	2021-08-25
RU2019140834A (ru)	2021-06-15
IL310731A (en)	2024-04-01
LT3634463T (lt)	2024-01-10
WO2018207026A3 (en)	2019-02-07
SMT202300407T1 (it)	2024-01-10
AU2024202977A1 (en)	2024-05-23
WO2018207026A2 (en)	2018-11-15
US10286036B2 (en)	2019-05-14
SI3634463T1 (sl)	2024-04-30
EP3634463A4 (en)	2021-03-17
EP4257138A3 (en)	2024-01-03
CA3063040A1 (en)	2018-11-15
IL270552B2 (en)	2024-07-01
EP3634463B1 (en)	2023-09-27
AU2018266850A2 (en)	2020-02-06
EP4257138A2 (en)	2023-10-11
PT3634463T (pt)	2023-12-05
AU2018266850A1 (en)	2020-01-02
AU2018266850B2 (en)	2024-02-08
MY203070A (en)	2024-06-06
ZA201907460B (en)	2020-11-25
IL270552B1 (en)	2024-03-01
HUE064984T2 (hu)	2024-04-28
CL2019003249A1 (es)	2020-07-10
ES2965454T3 (es)	2024-04-15
KR102710584B1 (ko)	2024-09-27

Publication	Publication Date	Title
DK3570844T3 (da)	2023-11-13	Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3728271T3 (da)	2022-12-19	Makrocykliske forbindelser til behandling af sygdomme
DK3143025T3 (da)	2019-12-09	Forbindelser til behandling af spinal muskelatrofi
DK3192902T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3325443T3 (da)	2022-07-18	Fremgangsmåde til fremstilling af pridopidin
DK3609529T3 (da)	2021-10-11	Rna til behandling af autoimmune sygdomme
DK3390390T3 (da)	2021-12-06	Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3193880T3 (da)	2020-06-02	Hæmning af den transiente receptor-potential-A1-ionkanal
DK3503890T3 (da)	2025-01-27	Anvendelse af pridopidin til behandling af dystonier
DK3436074T3 (da)	2020-08-03	Thiazolidforbindelser til behandling af virale infektioner
DK3460102T3 (da)	2020-07-13	Fremgangsmåde til fremstilling af en elektrokatalysator
DK3324824T3 (da)	2024-12-02	Fremgangsmåde til behandling af binokulare dysfunktioner
DK3318115T3 (da)	2020-04-14	Maskine til behandling af svinegylle
DK3280408T3 (da)	2020-02-03	Fremgangsmåde til fremstilling af dicycloplatin
DK3307267T3 (da)	2019-07-01	Behandling af multipel sklerose
DK3261661T3 (da)	2024-01-15	Menotropin til behandling af infertilitet
DK3634463T3 (da)	2023-11-27	Forbedret protokol til behandling af lupus nephritis
DK3390407T3 (da)	2023-11-06	Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
DK3573620T3 (da)	2023-03-20	Sammensætninger til behandling af hypertension
DK3662925T3 (da)	2021-06-28	Sammensætning, der omfatter fsh, til behandling af infertilitet
DK3344655T5 (da)	2024-10-07	Brug af anti-cd40-antistoffer til behandling af lupus nefritis
DK3302573T3 (da)	2019-11-11	Sammensætning til behandlingen af hjernelæsioner
DK3724173T3 (da)	2022-01-03	Forbindelser til behandling af neuromuskulære lidelser
DK3458467T3 (da)	2020-12-14	Fremgangsmåde til 6,7-alfa-epoxidering af steroid-4,6-diener
DK3478713T3 (da)	2022-06-20	Sammensætninger til behandling af amyloidose